Zhonghong Eric Guan

Zhonghong Eric Guan

Company: Mural Oncology

Job title: SVP, Head of Medical Affairs


Exploring Nemvaleukin Alfa Monotherapy & in Combination With Pembrolizumab in Patients With Advanced Solid Tumors 11:30 am

Outlining nemvaleukin as a novel engineered cytokine Revealing the design to selectively bind to intermediate-affinity interleukin-2 receptor (IL-2R) for preferential activation and expansion of tumor-killing CD8+ T cells and natural killer (NK) cells, with minimal expansion of regulatory T cells (Tregs) Discussing the potential to reduce native IL-2’s toxicities, thus allowing greater tolerability and efficacy…Read more

day: Conference Day Two

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.